Back to top
more

Edesa Biotech (EDSA)

(Delayed Data from NSDQ)

$4.37 USD

4.37
2,708

-0.05 (-1.13%)

Updated Apr 29, 2024 02:42 PM ET

After-Market: $4.02 -0.35 (-8.01%) 6:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Brokerage Reports

Research for EDSA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Edesa Biotech, Inc. [EDSA]

Reports for Purchase

Showing records 1 - 18 ( 18 total )

Company: Edesa Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

02/14/2024

Company Report

Pages: 5

Fiscal 1Q24 Results; EB05 Funding Secured; EB01 Results Look Solid; Reiterate Buy and $21 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Edesa Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

11/29/2023

Company Report

Pages: 5

Post-Split Model and Pipeline Forecast Changes; Reiterate Buy With an Adjusted PT of $21

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Edesa Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

11/22/2023

Company Report

Pages: 4

Final Phase 2b Data Provides Insight Into EB01 Efficacy; Reit Buy and $10 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Edesa Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

08/15/2023

Company Report

Pages: 3

Conditions for a Rapid EB05 Pivotal Study Challenging; Reiterate Buy With PT Adjusted to $10

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Edesa Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

05/24/2023

Company Report

Pages: 4

Regulatory and Pipeline Progress; Reiterate Buy and $16 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Edesa Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

03/15/2023

Daily Note

Pages: 3

FDA Agrees to EB05 Phase 3 Primary Endpoint; Reiterate Buy and $16 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Edesa Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

02/14/2023

Company Report

Pages: 5

EB05 Phase 3 Trial Approval Pending and Full EB01 Phase 2b Data Analysis Ahead; Reiterate Buy and $16 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Edesa Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

01/17/2023

Company Report

Pages: 4

Favorable Top-line EB01 Results in Chronic Allergic Contact Dermatitis; Reiterate Buy and $16 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Edesa Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

12/20/2022

Company Report

Pages: 5

EB01 Phase 2b Top-Line Data on Track for 1Q23; Reiterate Buy and $16 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Edesa Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

12/20/2022

Daily Note

Pages: 3

EB05 Receives Fast Track Designation; Reiterate Buy Rating and $16 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Edesa Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

11/28/2022

Company Report

Pages: 5

Potential EB05 Utility in Difficult-to-Treat COVID-19 Remains Underappreciated; Reiterate Buy Rating and $16 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Edesa Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

09/08/2022

Daily Note

Pages: 3

Expecting EB01 Phase 2b Study Primary Endpoint Within 30 Days; Reiterate Buy and $16 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Edesa Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

08/17/2022

Company Report

Pages: 5

EB05 and EB01 Continue to Make Progress; Reiterate Buy and $16 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Edesa Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

04/20/2022

Company Report

Pages: 5

Momentum Building in EB05 and EB01 Clinical Progress; Reiterate Buy and $16 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Edesa Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

01/04/2022

Company Report

Pages: 4

EB05 and EB01 Momentum Going Into 2022 Looking Strong; Reiterate Buy Rating and $16 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Edesa Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

12/20/2021

Company Report

Pages: 35

Edesa Gets Inflammation Under Control; Initiating Coverage With a Buy Rating and $16 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 35.00

Research Provided by a Third Party

Company: Edesa Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for EDSA

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Edesa Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

08/21/2020

Company Report

Pages: 6

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party